SCHEMBL5055256

SCHEMBL5055256

O=C(O)c1ccccc1NC(=O)N1CCN(c2cnc3ccccc3n2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 19/20 1.00
FAAH O00519 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13666109 0.96 HCAR2 (1.00) HCAR2FAAH
SCHEMBL5056830 0.93 HCAR2 (0.86) HCAR2FAAH
SCHEMBL13666072 0.91 HCAR2 (1.00) HCAR2FAAH
SCHEMBL12671399 0.91 HCAR2 (1.00) HCAR2FAAH
SCHEMBL13666065 0.89 HCAR2 (1.00) HCAR2FAAH
SCHEMBL5055304 0.88 HCAR2 (0.78) HCAR2FAAH
SCHEMBL13666074 0.87 HCAR2 (1.00) HCAR2FAAH
SCHEMBL13666093 0.87 HCAR2 (1.00) HCAR2FAAH
SCHEMBL13668597 0.86 HCAR2 (0.78) HCAR2FAAH
SCHEMBL13666064 0.86 HCAR2 (0.78) HCAR2FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080139565-A1 Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia SMITHKLINE BEECHAM CORPORATION 2008-06-12 US claimed
WO-2011057110-A1 GPR109A AGONISTS FOR THE TREATMENT OF CEREBRAL ISCHEMIA RUPRECHT-KARLS-UNIVERSITAT-HEIDELBERG (DE) 2011-05-12 WO disclosed
US-20090258862-A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-20090258862-A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-20080139565-A1 Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia SMITHKLINE BEECHAM CORPORATION 2008-06-12 US disclosed
US-20080139565-A1 Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia SMITHKLINE BEECHAM CORPORATION 2008-06-12 US disclosed
US-20080139565-A1 Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia SMITHKLINE BEECHAM CORPORATION 2008-06-12 US disclosed
EP-1848707-A1 AWTHRANILIC ACID DERIVATIVES AND THEIR USE IN TREATMENT OF DISEASES OF LIPID METABOLISM, IN PARTICULAR DYSLIPIDAEMIA SMITHKLINE BEECHAM CORPORATION (US) 2007-10-31 EP disclosed
WO-2007027532-A2 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 2007-03-08 WO disclosed
WO-2006085108-A1 AWTHRANILIC ACID DERIVATIVES AND THEIR USE IN TREATMENT OF DISEASES OF LIPID METABOLISM, IN PARTICULAR DYSLIPIDAEMIA SMITHKLINE BEECHAM CORPORATION (US) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258862-A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment LDLR, APOB, FFAR1 HCAR2 23/4885FAAH 769/4885
US-20080139565-A1 Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia ANTXR2, CYP46A1, HCAR1 HCAR2 16/4885FAAH 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.